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ABSTRACT
Chemotherapeutics, including the platinum compounds oxaliplatin (OXP) and cisplatin (CDDP), are
standard care of treatment for cancer. Although chemotherapy has long been considered
immunosuppressive, evidence now suggests that certain cytotoxic agents can efﬁciently stimulate
antitumor responses, through the induction of a form of apoptosis, called immunogenic cell death (ICD).
ICD is characterized by exposure of calreticulin and heat shock proteins (HSPs), secretion of ATP and
release of high-mobility group box 1 (HMGB1). Proper activation of the immune system relies on the
integration of these signals by dendritic cells (DCs). Studies on the crucial role of DCs, in the context of
ICD, have been performed using mouse models or human in vitro-generated monocyte-derived DCs
(moDCs), which do not fully recapitulate the in vivo situation.
Here, we explore the effect of platinum-induced ICD on phenotype and function of human blood
circulating DCs. Tumor cells were treated with OXP or CDDP and induction of ICD was investigated. We
show that both platinum drugs triggered translocation of calreticulin and HSP70, as well as the release of
ATP and HMGB1. Platinum treatment increased phagocytosis of tumor fragments by human blood DCs
and enhanced phenotypic maturation of blood myeloid and plasmacytoid DCs. Moreover, upon
interaction with platinum-treated tumor cells, CD1cC DCs efﬁciently stimulated allogeneic proliferation of
T lymphocytes. Together, our observations indicate that platinum-treated tumor cells may exert an active
stimulatory effect on human blood DCs. In particular, these data suggest that CD1cC DCs are critical
mediators of immune responses induced by ICD.
Abbreviations: APC, antigen-presenting cell; ATP, adenosine triphosphate; CDDP, cis-diamino-dichloro-platinum (II)
cisplatin; CRT, calreticulin; CTC, circulating tumor cell; DC, dendritic cell MHC; HMGB1, h igh -mob i l i t y group
box 1 ; HSP, heat shock protein; ICD, immunogenic cell death; IL, interleukin; inﬂDC, inﬂammatory dendritic cell;
mDC, myeloid dendritic cell; MHC, major histocompatibility complex; MLR, mixed lymphocyte reaction; moDC,
monocyte -de r i ved dendritic cell; OXP, oxaliplatin; PBL, peripheral blood leukocyte; PBMC, peripheral blood
mononuclear cell; pDC, plasmacytoid dendritic cell; TLR, toll-Like receptor
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Introduction
Platinum-based chemotherapy is currently approved as ﬁrst-
line treatment for several malignancies, including colon and
testicular cancer.1 Besides a direct cytotoxic effect on tumor
cells, some chemotherapeutic compounds are now recognized
to have beneﬁcial effects on the immune system, which may
contribute to their clinical effectiveness.2-7 Accordingly, a num-
ber of anticancer drugs, including the platinum-based com-
pound oxaliplatin (OXP), were shown to be more effective
against tumors established in immunocompetent, as opposed
to immunodeﬁcient mice.5 This was predicated on the ability
of these drugs to induce a form of cell death that activated the
immune system and promoted antitumor immune responses.
As such, these agents are referred to as immunogenic cell death
(ICD)-inducers.8
ICD-inducers cause severe cell stress, which activates dis-
tinct molecular pathways that can result in the induction of
apoptosis.4 Classically, ICD requires three molecular events,
which may or may not be linked. First is the translocation of
chaperone molecule calreticulin from the lumen of the endo-
plasmic reticulum (ER) to the cell surface (ecto-CRT).9,10 Ecto-
CRT serves as an “eat me” signal that marks tumor cells for
engulfment by phagocytic cells.9 Second is the active secretion
of ATP into the extracellular environment, which acts as a
CONTACT Carl G. Figdor Carl.Figdor@radboudumc.nl Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, PO Box 9101, 6500 HB
Nijmegen, the Netherlands.
Supplemental data for this article can be accessed on the publisher’s website.
*These authors contributed equally to this work.
Published with license by Taylor & Francis Group, LLC © Stefania Di Blasio, Inge M.N. Wortel, Diede A. G. van Bladel, Laura E. de Vries, Tjitske Duiveman-de Boer, Kuntal Worah, Nienke de Haas,
Sonja I. Buschow, I. Jolanda M. de Vries, Carl G. Figdor, and Stanleyson V. Hato.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unre-
stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
ONCOIMMUNOLOGY
2016, VOL. 5, NO. 8, e1192739 (14 pages)
http://dx.doi.org/10.1080/2162402X.2016.1192739
chemoattractant for immune cells and directs the differentia-
tion of myeloid precursors into inﬂammatory cells.11,12 Thirdly,
release of high-mobility group box 1 (HMGB1) into the extra-
cellular milieu, which is required for optimal induction of T
cell-mediated antitumor responses.13 Other than the three
“hallmarks” of ICD, the ER-resident chaperones, heat shock
proteins (Hsp) Hsp70 and Hsp90, are exposed on the mem-
brane of cells undergoing severe stress. These molecules are not
included in the canonical deﬁnition of ICD, nevertheless they
also act as danger signals and might contribute to the stimula-
tion of antigen-presenting cells (APCs).14
Induction of a systemic tumor-speciﬁc immune response by
ICD requires the recognition and integration of these separate sig-
nals (ecto-CRT, ATP, andHMGB1) into one command that drives
T cell activation. Dendritic cells (DCs) are one of themain cell types
that serve this role. They are the main APCs that link innate and
adaptive immunity. DCs can encounter tumor cells in two ways.
First, the chemoattractants ATP and HMGB1 induce intratumoral
recruitment of DCs.11 Secondly, tumor cells that have detached
from the tumor bulk are likely to enter blood circulation, facilitat-
ing their spread to distant locations in the body.15 In the blood
stream, these circulating tumor cells (CTCs) can encounter blood-
circulating DCs. Platinum-induced exposure of ICD-markers
might contribute to make CTCs “visible” andmore sensitive to DC
recognition. Indeed, treatment with well-known ICD-inducers,
anthracyclines, induced ecto-CRT expression on CTCs in vivo.16
Chemotherapy treated-tumor cells are engulfed by immature DCs,
which then undergo maturation. Mature DCs process and present
tumor antigens to naive cytotoxic lymphocytes, prompting antitu-
mor responses.7,16 Accordingly, perturbation of key elements of
adaptive immunity, such as in vivo depletion of DCs, or knockout
of DC receptors, resulted in failure to prime an antitumor response
in chemotherapy-treatedmousemodels.5,13,17
There are two major DC subsets circulating in human
peripheral blood, myeloid DCs (mDCs), and plasmacytoid DCs
(pDCs).18 Classically, myeloid DCs are subdivided into CD16C,
CD1cC, and CD141C DCs, based on the expression of speciﬁc
surface molecules.19 However, genome-wide expression proﬁle
analysis recently suggested that CD16C DCs may represent a
particular subset of monocytes, with DC-like properties.20 For
simplicity, we will refer to them as CD16C DCs. Transcrip-
tional, phenotypic, and functional studies highlight signiﬁcant
differences between human blood DCs, suggesting a biological
specialization of these DC subsets.21,22 Despite the great interest
that ICD has gained in the past decade, the role of naturally
occurring human DCs, especially for DCs that circulate in the
blood, in this process is poorly understood, as most studies
have been performed in murine models or with in vitro gener-
ated moDCs.11,23 Here, we study induction of ICD in human
tumor cells by two of the most widely used platinum com-
pounds, OXP and cisplatin (CDDP), and how that affects
human DC subsets. We report that, at clinically relevant con-
centrations, both compounds induced apoptosis of tumor cells,
which was accompanied by the expression and release of ICD-
associated molecules. Exposure of tumor cells to platinum
drugs resulted in increased uptake of tumor fragments by natu-
rally occurring blood DCs and stimulated DC maturation. Sur-
prisingly, only CD1cC DCs were subsequently able to drive
T cell proliferation.
Results
Cisplatin and oxaliplatin induce a form of cancer cell death
consistent with ICD
Up till now most studies on induction of ICD by platinum com-
pounds, OXP andCDDPwere performed inmousemodels and lit-
tle is known about the ability of platinum compounds to induce
ICD in human tumor cells.5,9 We investigated the molecular hall-
marks of platinum-induced cancer cell death in vitro. We treated
human colon (Caco2), testicular (833KE and 2102EP), and mela-
noma (BLM) cell lines with increasing, clinically relevant doses of
OXP or CDDP and studied cell death using Annexin V and DAPI
staining. Both OXP and CDDP decreased viability of BLM cells in
a time- and dose-dependent manner (Figs. 1A and B), as indicated
by increased phosphatidylserine exposure and stronger nuclear
DAPI staining. Similar cytotoxicity was observed for 833KE,
2102EP, and Caco-2 cells (data not shown). Given the chemosensi-
tivity of testicular carcinoma cells, 833KE and 2102EP cell lines
were treated with lower drug concentrations, compared to the
other cell lines studied. Despite sharing similar mechanisms of
action, OXP, but not CDDP, was previously described to trigger
exposure of ecto-CRT on the murine colon cancer cell line CT26.5
Surprisingly, we observed similar, if not stronger translocation of
ecto-CRT after BLM andCaco-2 cells were exposed to CDDP com-
pared to OXP (Figs. 1C–E; Fig. S1C). Analysis of expression kinet-
ics on BLM cells showed that ecto-CRT was detected as early as 1 h
after treatment and its exposure was dose- and concentration-
dependent (Figs. S1B and C). On the other hand, OXP and CDDP
had less marked effects on the translocation of ecto-CRT in 833KE,
2102EP and CT26 cell lines, at time and dosage tested (Figs. 1E and
F; Fig. S1C andD).
In order to simulate the pharmacokinetics of platinum treat-
ment, which is administered intravenously and remain in the
body for a few hours,24 we exposed cells to OXP or CDDP for
8 h, washed away the drug and cultured the cells for an addi-
tional 40 h under drug-free conditions. This short-term drug
exposure to OXP or CDDP dose-dependently decreased viabil-
ity of BLM cells and induced ecto-CRT expression (Figs. 1G
and H), similar to long-term (48 h) treatment (Figs. 1B and C).
Next, wemeasured the expression of Hsp70, ATP, andHMGB1
on different tumor cell lines treated with platinum drugs. Both
OXP and CDDP induced translocation of Hsp70 (ecto-Hsp70) to
the cell surface of human BLM and 2102EP cells, as well as the
murine CT26 cell line as observed using ﬂow cytometry (Figs. 2A–
C; Figs. S2A–C). Concurrent with increased ecto-HSP70, we
observed increased secretion of ATP (Figs. 2D–F; Fig. S2D) and
HMGB1 (Figs. 2G–I, Figs. S2E and F) in the supernatant of plati-
num-treated tumor cells. In all, we show that both OXP and
CDDP cause apoptosis of human tumor cells, with the concomi-
tant translocation of ecto-CRT and ecto-HSP and the extracellular
release of ATP and HMGB1. These results suggest that both plati-
num compounds induce a form of cell death that fulﬁlls the
requirements for immunogenic apoptosis.
Human DCs preferentially phagocytose platinum-treated
tumor cells in a CRT-dependent manner
We investigated whether platinum-induced ecto-CRT had an effect
on the recognition and uptake of tumor cells by human blood
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DCs.9 First, we examined whether treatment with platinum drugs
led to increased interaction between tumor cells and human blood
DCs using confocal microscopy. For this experiment, the human
melanoma cell line BLM was modiﬁed to stably express the
ﬂuorescent protein GFP (hereafter referred to as BLM-GFP).
Untreated BLM and BLM-GFP showed no difference in surface
expression of calreticulin (CRT). Furthermore, platinum-treatment
induced comparable upregulation of CRT on both BLM and BLM-
Figure 1. (For ﬁgure legend, see page 4).
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GFP (Fig. S3B). Tumor cells were left untreated or treated with
OXP or CDDP for 48 h and then co-cultured with CD1cC DCs for
3 h. We observed increased interaction between DCs and tumor
cells treated with CDDP or OXP compared to untreated cells
(Figs. 3A and B). Based on the fact that tumor cells are several
orders of magnitude larger than blood DCs, we hypothesized that
DCs, in contrast to macrophages, do not ingest whole tumor cells
but only subcellular fragments of these cells. To evaluate whether
fragments of platinum-treated cells are preferentially taken up by
the three humanDC subsets examined in this study, we established
in vitro co-cultures of platinum-treated tumor cells and DCs.
Tumor cells were exposed to OXP or CDDP. Concentration and
duration of treatment with platinum drugs were speciﬁcally chosen
for each cell line in order to maximize induction of ICD hallmarks,
while maintaining cell viability at the start of the co-culture. Fluo-
rescently labeled-tumor cells were co-cultured with DCs for 24 or
48 h. Uptake of untreated versus OXP- or CDDP-treated tumor
cells was assessed by ﬂow cytometry (Figs. 3C–F; Fig. S3). In order
to distinguish between binding of tumor cells fragments to the cell
membrane of DCs and active uptake, we performed co-culture
experiments at 4C vs. 37C, respectively. As shown in Fig. 3C,
DCs are capable of taking up (37C) fragments of tumor cells. In
contrast, there is a low level of binding (4C) of tumor fragments to
DCs, which did not increase upon treatment (Fig. 3C; Fig. S3C).
Furthermore, while there was a considerable increase in the uptake
of platinum treated cells between 24 and 48 h of co-culture, uptake
of control cells was not markedly increased in time (Fig. 3D).
Distinct DC subsets have different capacities to phagocytose
soluble and cell-associated tumor antigens.22 We therefore
tested the capacity of CD1cC DCs, CD16C DCs, and pDCs to
take up OXP- or CDDP-treated tumor cells. Treatment of BLM
cells with CDDP led to a signiﬁcant increase in the uptake of
tumor fragments by all DC subsets. Plasmacytoid DCs were the
least efﬁcient DC subset in engulﬁng tumor-derived particles,
whereas CD1cC and CD16C DCs were more proﬁcient
(Fig. 3E). These results were consistent across different cell lines
(833KE, 2102EP, and Caco2) used in the co-culture with
CD1cC and CD16C DCs (Fig. 3F). OXP was less potent than
CDDP in inducing uptake of BLM cells (Fig. 3E), in contrast to
the other cell lines tested, for which OXP was slightly more
potent than CDDP (Fig. 3F). These differences might be due to
differences in drug uptake in the different cell lines.
We wondered whether uptake of tumor fragments was solely
dependent on CRT expression and thus performed the uptake
experiment in the presence of a CRT-blocking peptide.25,26 An
irrelevant peptide (derived from gp100) or a mouse isotype
antibody were used as negative controls (Fig. 4A; Fig. S3D). As
expected, the irrelevant peptide, as well as, the non-speciﬁc IgG
control, did not affect phagocytic ability of CD1cC DCs. How-
ever, engagement of ecto-CRT with a CRT-blocking peptide
completely abolished uptake of tumor cells, including those
treated with platinum drugs. This observation conﬁrmed the
crucial role played by CRT in directing tumor cell fragment
uptake. The most commonly described receptor for ecto-CRT
is the low-density lipoprotein receptor-related protein 1
(LRP1), also known as CD91.27 The expression of CD91 on dis-
tinct human blood circulating DC subsets has not been charac-
terized before, thus we analyzed CD91 expression on
CD1cCDCs, CD16C DCs, and pDCs by ﬂow cytometry. Mono-
cytes (CD14C) were previously shown to express CD91 and
were used as a positive control (Fig. 4B).28 Both CD1cC and
CD16C DCs, as well as monocytes, clearly expressed the ecto-
CRT receptor. On the other hand, and consistent with the low
uptake of chemotherapeutically-induced tumor cell fragments,
pDCs showed little-to-no expression of CD91. We observed a
similar trend looking at the transcriptomes of these DC subsets
(Fig. 4C). mRNA levels of CD91 were highest in CD16C and
CD1cCDCs, whereas pDCs showed the lowest expression. Sub-
sequent blocking of CD91 on CD1cCDCs, with a speciﬁc anti-
CD91 blocking antibody, however, did not affect phagocytosis
of tumor cells, despite its high expression levels (Fig. 4D). To
complement this analysis, we also investigated the expression
of alternative receptors for ecto-CRT. Both the scavenger recep-
tor class-A (SR-A, also known as CD204) and the scavenger
receptor expressed by endothelial cell-1 (SREC-I) were reported
to bind ecto-CRT.29,30 Transcriptomic analysis of SR-A and
SREC-I revealed that these receptors are variably expressed on
blood DC subsets, with CD1cC DCs again showing the highest
expression (Fig. 4C). Taken together, our data demonstrate
that blood DCs take up platinum-treated tumor cells more efﬁ-
ciently than untreated cells and this uptake is strictly dependent
on CRT exposure. Additionally, while we observed uptake of
tumor fragments by all DC subsets, they differentially express
receptors capable of binding ecto-CRT.
Phagocytosis of platinum-treated tumor cells induces
maturation of human DC subsets
Next, we investigated whether the CRT-mediated uptake of
tumor cells fragments may lead to DC maturation. The tran-
scriptomes of DCs for receptors that sense danger signals
released by dying tumor cells were assessed. CD1cC DCs
showed the highest mRNA expression levels of the P2RY2 (rec-
ognizing ATP), LOX-1 (HSPs), and RAGE (HMGB1) recep-
tors; as well as, of the common receptors for HSPs and
HMGB1 (TLR2) (Fig. 4C). Exceptions were P2RX7 (ATP) and
Figure 1. (see previous page) Sensitivity of tumor cell lines to platinum drugs and platinum-mediated exposure of ecto-CRT. (A, B) Frequency of apoptotic (Annexin VC
DAPI¡) and secondary necrotic (Annexin VC DAPIC) BLM cells after treatment with OXP or CDDP. Human melanoma BLM cells were cultured with platinum drugs or left
untreated, for 24 or 48 h. Cells were stained with Annexin-V-FITC and DAPI and analyzed by ﬂow cytometry. Data are presented as representative contour plot (A) or
mean§SEM (at least nD 2, performed in duplicates) (B). (C, E, F) CRT exposure was assessed on Annexin VC DAPI¡ cells after treatment with OXP or CDDP by ﬂow cytom-
etry. BLM cells were treated as described above. Data are relative mean§SEM (at least n D 3, in duplicates) (C). Representative histograms show CRT expression (MFI) on
human colon (Caco-2) and testicular (833KE and 2102EP) cancer cell lines following 24 h of treatment with OXP or CDDP. Caco-2 were treated with 15 mM of OXP or
CDDP; 833KE and 2102EP were treated with 6.3 mM OXP or 8.3 mM CDDP. Isotype (gray line), control (gray ﬁlled histogram), treatment (black thick line) (E). Exposure of
CRT on murine colon cancer CT26 cells was assessed after 24 h of treatment with 15 mM of OXP or CDDP. Data are means of duplicates of one representative experiment
(F). (D) CRT expression was conﬁrmed by confocal microscopy. BLM cells were stained with an anti-CRT antibody and the membrane marker, wheat germ agglutinin
(WGA). Scale bar 10 mm. (G, H) Frequency of apoptotic vs. necrotic cells (F) and CRT exposure (G) on BLM cells, after short-term (8 h) drug exposure to OXP or CDDP, at
indicated doses. Results are mean§SEM (n D 3 in duplicates). Signiﬁcance was determined with One-way ANOVA, p < 0.05, p < 0.001, as compared to control
(CTRL) cells.
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TLR4 (HSPs and HMGB1), for which CD16C DCs had higher
mRNA expression levels (Fig. 4C). On the other hand, pDCs
showed the lowest expression of all these receptors on mRNA
level (Fig. 4C).
Following co-culture with platinum-treated tumor cells, we
measured surface expression of several markers on DCs, involved
in antigen presentation and co-stimulation (Figs. 5 and 6). As a
positive control, DCs were stimulated with TLR ligands (poly I:C
(pI:C) or R848). Co-culture of DCs with platinum-treated BLM
cells induced a signiﬁcant upregulation of co-stimulatory mole-
cules, CD80 andCD86. Although pDCswere less efﬁcient in taking
up tumor fragments (Fig. 3E), upregulation of co-stimulatory mol-
ecules (CD80 and CD86) was more prominent in pDCs than
CD1cC or CD16C DCs (Fig. 5A), despite the lower expression of
receptors recognizing the dying cell fragments on these cells. In
addition, we analyzed the expression of major histocompatibility
complex (MHC) classes I and II, required for antigen presentation
to T cells. Platinum-treatment only moderately inﬂuenced MHC I
and II expression on DC subsets (Fig. 5B). We observed similar
effects of platinum treatment for 2102EP (Figs. 6A and B) and
833KE (Figs. 6C and D) cells co-cultured with CD1cC or CD16C
DCs (Fig. S4).
In addition to phenotypical maturation, we tested cytokine
secretion in the supernatant of tumor-DC co-cultured over-
night upon induction of ICD (Figs. 5C and D). CD1cC DCs
markedly increased the production of the proinﬂammatory
cytokine, TNF-a, as well as the anti-inﬂammatory cytokine, IL-
10, in response to interaction with both OXP- and CDDP-
treated BLM cells. On the other hand, CD16C DCs and pDCs
showed no signiﬁcant response to platinum-treated tumor cells.
Furthermore, we could not detect any IL-2, IL-4, IL-5, IL-12,
TNF-b, and IFNg (data not shown).
Platinum-treated tumor cells stimulate human CD1cC DCs
to induce a T cell response
Co-culture of DCs with different platinum-treated tumor cell
lines (BLM, 2102 EP, and 833KE) led to uptake of tumor cells
and subsequent maturation of DC. Next, we investigated the
ability of these mature DCs to stimulate allogeneic T cell prolif-
eration. Proliferation of CD3C T cells was quantiﬁed by mea-
suring CFSE dilution in a mixed lymphocyte reaction (MLR)
(Fig. 7A, Fig. S5). As shown in Fig. 7b, CD16C DCs were not
able to induce signiﬁcant T cell proliferation in any of the
Figure 2. Platinum drugs induce release of immunogenic signals for DCs stimulation. (A, B, C) Surface expression of Hsp70 on BLM (A), 2102EP (B), and CT26 (C) cells, after
platinum treatment, was assessed on Annexin VC DAPI¡ cells by ﬂow cytometry. Cells were cultured with OXP or CDDP at indicated doses, for 24 (2102EP and CT26) or
48 h (BLM). Data are presented as mean (n D 2) (D, E, F). Extracellular ATP was measured by luciferase assay, in supernatants of cells cultured as described above. Results
represent relative means§SEM (at least n D 2, done in duplicates). (G, H, I) Elisa detection of HMGB1 release in supernatant of cells cultured as described above. Data are
means§SEM (at least n D 2). Signiﬁcance was determined with One-way ANOVA, p < 0.05, p < 0.01, p < 0.001, as compared to control (CTRL) cells.
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conditions tested. On the other hand CD1cC DCs co-cultured
with OXP- or CDDP-treated tumor cells, showed a signiﬁcant
increase in T cell proliferation compared to untreated cells.
Plasmacytoid DCs were able to induce allogeneic T cell prolif-
eration but there was no difference between pDCs co-cultured
with untreated cells or platinum-treated cells. Altogether these
results seem to suggest that CD1cC DCs are most effectively
activated by tumor cells undergoing ICD and might have the
potency to drive subsequent immune responses.
Discussion
The human immune system plays a fundamental role in tumor
recognition and control.31 Recent advances, including the dis-
covery of ICD and its contribution to clinical efﬁcacy, suggest
that durable clinical responses to chemotherapy require the
presence of a functional immune system.3,32,33 DCs are the key
cells in this scenario, as they are required to kick-start effective
adaptive immune responses.34-36
Here, we study the function of the three most abundant
human blood circulating DCs (CD1cC DCs, CD16C DCs, and
pDCs) in ICD induced by two of the most used platinum drugs,
OXP and cisplatin (CDDP). We observed that, contrary to previ-
ous reports, both drugs were able to induce expression of the
three hallmarks of ICD: CRT exposure, secretion of ATP, and
release of HMGB1. Furthermore, we show that all three DC sub-
sets preferentially take up fragments derived from platinum-
treated tumor cells and subsequently undergo phenotypical
maturation.
Although the ﬁrst compounds discovered to initiate an immu-
nogenic form of apoptosis were structurally similar and all
belonged to the class of the anthracyclines, the list of ICD inducers
has since been expanded.5,37-40 Previously, Tesniere et al. found
that the platinum drug CDDP fails to initiate ICD by itself, despite
Figure 3. Platinum-treatment increases phagocytosis of tumor cells by human DC subsets. (A, B) BLM-GFP cells were treated with 15 mM OXP or CDDP for 48 h and co-
cultured with CD1cC DCs (pre-labeled with PKH26) for 3 h. Representative confocal image (A) and quantiﬁcation (B) of BLM-DC interactions. A total of ﬁve images per
sample were taken and the number of interactions was normalized over the number of DC and BLM cells present in the image. Data represent mean§SEM of one repre-
sentative experiment. (C) Percentage of uptake (48 h co-culture, 37C, gray bar) of 15 mM OXP or CDDP treated-BLM cells by CD1cC DCs versus binding (4C, white bar).
Values are relative to binding of control (CTRL) BLM cells and show mean (n D 2). (D) Representative contour plot of control (CTRL) or platinum treated-BLM cells uptake
by CD1cC DCs upon 24 or 48 h of co-culture. (E, F) Percentage of phagocytosis of BLM (E), 833 KE, 2102 EP, Caco2 (F) human tumor cell lines by different DC subsets
(CD16C, CD1cC, and pDCs). BLM and Caco-2 were treated with 15 mM of OXP or CDDP for 48 h; 833KE and 2102EP were treated with 6.3 mM OXP or 8.3 mM CDDP for
24 h. CTRL (white bar) or treated tumor cells (gray or black bars) were co-cultured with DCs for 48 h and extend of uptake was assessed by ﬂow cytometry. The graph
shows the mean§SEM (at least n D 2, in duplicate). Signiﬁcance was determined by Two-way ANOVA, p < 0.01, p< 0.001, as compared to CTRL cells.
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its similarity in structure and function to the ICD-inducer OXP.4,5
Nonetheless, CDDP was converted into an ICD inducer by exoge-
nous co-administration of Cxcl2 (ortholog of the human pro-
inﬂammatory cytokine/chemokine IL-8).41 Here, we show that
CDDP, as well as OXP, could upregulate exposure of ecto-CRT
and induce release of ATP and HMGB1 in human tumor cells of
distinct origins. Our observation that the human melanoma cell
line BLM secretes high amounts of IL-8 (data not shown) could be
a possible explanation for the discrepancy between our study and
the results of Tesniere et al. This suggests that different cell lines
may have distinct intrinsic potentials to emit immunogenic signals.
In apparent accordance with this notion, UV irradiation has been
described to induce ICD in murine models, yet it failed to do so in
human cancer cell lines tested in another study.23,40 In addition to
OXP and CDDP, widely used in clinical practice, other platinum
drugs, such as carboplatin, might be relevant in the context of ICD.
These platinum analogs differ in their toxicity proﬁles and efﬁcacy
in distinct malignancies, therefore understanding their potential as
ICD inducers might be useful for improving therapeutic
outcomes.42
In addition to the three ICD hallmarks described above, sur-
face translocation of the heat shock protein Hsp70 could
expand the general deﬁnition of ICD.23,39 We here report that
both OXP and CDDP were able to upregulate expression of
Hsp70 in various human tumor cell lines.
Treatment of human tumor cells with OXP or CDDP
increased uptake of tumor fragments by all three human DC
subsets. As previously reported,22 CD1cC and CD16C DCs efﬁ-
ciently phagocytosed cell fragments, whereas pDCs showed
lower uptake capacity. This uptake was dependent on ecto-
CRT, however blocking of the CRT receptor did not abrogate
tumor cell fragment uptake, suggesting that other receptors
might be involved. The multi-ligand scavenger receptors SR-A
(CD204) and scavenger receptor expressed by endothelial cell-
1 (SREC-I), have been proposed to be involved in ecto-CRT
binding.29,30 Our transcriptome analysis of blood DC subsets
Figure 4. Human DCs take up platinum-treated tumor cells in a CRT-dependent manner. (A) Percentage of uptake of 15 mM OXP or CDDP treated-BLM cells by CD1cC
DCs. Control or treated tumor cells were co-cultured with DCs in the presence of isotype (white bar), CRT blocking peptide (gray bar) or irrelevant tumor antigen (gp100)
peptide (black bar) for 2 h. Extent of uptake was assessed by ﬂow cytometry. Data show means of duplicates of one representative experiment. (B) Representative histo-
grams showing CD91 expression on human monocytes (CD14C) and DCs (CD16C, CD1cC, and pDCs). Isotype (gray ﬁlled histogram), anti-CD91 (black thick line). (C) Heat-
map of relative mRNA expression levels of genes in human DC subsets. Heatmap shows the normalized expression of genes (Z-scores) in CD16C, CD1cC, and pDCs. Data
are represented from three healthy donors. (D) Representative contour plot of CTRL or CDDP (15 mM, 48 h) treated-BLM cells uptake by CD1cC DCs upon functional block-
ing of CD91 on DCs. BLM cells and DCs were co-cultured overnight in the presence of isotype control or CD91-blocking antibody. Percentage of phagocytosis was assessed
by ﬂow cytometry.
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conﬁrms that SR-A and SREC-I are expressed on distinct
human DCs.43 The presence of these alternative receptors
might explain why blocking of CD91 did not diminish the
uptake. Furthermore, we cannot exclude the possibility that
there may be more receptors involved in ecto-CRT binding and
that these have yet to be described. More research is required to
reveal which receptor is responsible for CRT-mediated uptake
on human DC-subsets.
The human DC population is characterized by high degree
of heterogeneity that reﬂects their phenotypical and functional
properties, as well as their location in the body.44 Consequently,
DCs can interact with tumor cells in multiple ways. Immature
DCs populate peripheral tissues and organs, where they are
committed to (tumor) antigen capture.44 In addition, myeloid
and plasmacytoid DC subsets are found circulating in the
blood, where they may encounter CTCs that have detached
from the primary tumor and entered into the bloodstream.18
Furthermore, DCs can home to and inﬁltrate tumors. As an
example, inﬂammatory dendritic cells (inﬂDCS), were
described as a distinct subset of DCs originating from in situ
differentiation of monocytes recruited to the site of inﬂamma-
tion.45 In mice, monocytes were recruited into the tumor bed
within 12 h following mitoxantrone treatment, and differenti-
ated into inﬂDCs. Addition of a neutralizing antibody against
CD11b abrogated activation of tumor-speciﬁc CD8C T cells,
indicating that DCs play a central role in ICD-mediated initia-
tion of antitumor responses.11 In this perspective, distinct DC
subsets might be relevant as cellular mediators of ICD. Among
blood DC populations, CD141C DCs are also equipped with
the potent ability to cross-prime cytotoxic T lymphocytes.22
Figure 5. Phagocytosis of platinum-treated BLM cells induces maturation of human DC subsets. (A, B) The expression of maturation markers on DC subsets (CD16C,
CD1cC, and pDCs) following 48 h of co-culture with control or platinum treated BLM cells. DC stimulated with TLR ligands (4 mg/mL R848 for pDCs and 2 mg/mL poli(I:C)
for CD16C and CD1cC) were used as positive controls. The expression levels were determined by ﬂow cytometry and depicted as GeoMFI values, relative to those of the
co-culture with control tumor cells (coCTRL). The graphs show the mean§SEM (n D 7). Signiﬁcance was determined by One-way ANOVA, p < .05, p < 0.01, p <
0.001. (C, D) TNF-a and IL-10 production was analyzed in supernatants of overnight co-cultured pretreated-BLM and DCs by a multiplex FlowCytomix kit. Data are
mean§SEM (n D 5). Signiﬁcance was determined by 2-tailed t-test, p < .05.
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However, their scarce frequency represents a major hurdle in
investigating their role in many aspects of DC biology.
Stimulation of an effective T cell response is determined by
several critical steps. These include (tumor) antigen uptake,
processing, and (cross)-presentation, as well as phenotypical
and functional maturation of DCs.46,47 Murine DCs were
reported to upregulate maturation-associated markers upon
phagocytosis of bortezomib-treated colon cancer cells.48 Similar
effects were observed for human moDCs that were co-cultured
with Idarubicin- or Bortezomib-treated tumor cell lines.23,39
Accordingly, we showed that interaction of OXP- or CDDP-
treated tumor cells with blood DC subsets induced phenotypi-
cal maturation of DCs, observed as upregulation of co-stimula-
tory molecules (CD80 and CD86). In line with previous
observations,22 although pDCs were less able to take up
antigens from their environment than other subsets, they efﬁ-
ciently matured and induced high levels of co-stimulation.
Despite strong phagocytic ability and induction of maturation,
CD16C DCs appeared to be the least efﬁcient inducers of T cell
responses, probably due to their minimal cross-presenting
capacity.22 This seems to be in accordance with the hypothesis
that CD16C DCs may share some biological functions with
DCs, yet they are more similar to monocytes, based on the
comparison of their gene expression proﬁles.20 The most effec-
tive response was observed for CD1cC DCs. Notably, CD1cC
DCs were the only DC subset that, in response to interaction
with platinum-treated tumor cells, secreted TNF-a and IL-10,
cytokines typically induced upon exposure to different matura-
tion stimuli.49,50 This myeloid DC population was capable of
engulﬁng platinum-treated tumor cells, responding to
Figure 6. Phagocytosis of platinum-treated testicular cancer cells induces maturation of human DC subsets. The expression of maturation markers on DC subsets (CD16C,
CD1cC, and pDCs) following 48 h of co-culture with control or platinum treated 2102EP (A, B) or 833KE (C, D) cells. The expression levels were determined by ﬂow cytom-
etry and depicted as GeoMFI values, relative to those of the co-culture with control tumor cells (coCTRL). The graphs show the mean (n D 2).
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activatory signals and inducing T cell proliferation. In support
of the functional observations, our transcriptomic analysis
revealed that CD1cC DCs had higher expression of DC recep-
tors sensing danger signals released by dying tumor cells, on
mRNA levels as compared to the other two DC subsets. Appro-
priately, deﬁciency or loss-of-function mutations of genes
encoding these receptors, was shown to compromise the efﬁ-
cacy of anticancer chemotherapy, stressing their crucial role in
ICD.5,13,17
In summary, we have investigated for the ﬁrst time the role
of the three most abundant human blood DC populations
(CD1cC DCs, CD16C DCs, and pDCs) in the context of ICD
and show that only CD1cC DCs were capable of inducing allo-
geneic T cell response in vitro. Moreover, we expanded the list
of ICD inducers, showing that—similarly to OXP—CDDP
induces a form of tumor cell death consistent with ICD.
Together, these observations point toward an active stimulatory
effect of platinum-treated tumor cells on DCs that naturally
occur in the human body and may contribute to the translation
of current knowledge on ICD into clinical settings.
Materials and methods
Cell culture, transduction, and stable cell line
Cells were cultured at 37C, 5% CO2. Human testicular carci-
noma (2102EP and 833KE) and murine colon carcinoma
(CT26) cell lines were cultured in RPMI 1640 (Gibco, Thermo
Fisher Scientiﬁc, catalog# 42401–018), supplemented with 10%
fetal calf serum (FCS, Greiner bio-one), and Ultra-glutamine
(Lonza, catalog# BE17-605E/U1). Human melanoma (BLM
and BLM-GFP) and colorectal adenocarcinoma (Caco-2) cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Gibco, 31966–021), with 5% or 20% FCS, respectively. The
Lenti6/Block-iT-shScramble (GFP) vector was a kind gift of
Prof. Peter Friedl (RIMLS, The Netherlands). The speciﬁc
scramble shRNA sequence has no homology to any known
mammalian gene. BLM cells were infected with lentiviral vector
and (10 mg/mL) polybrene and incubated at 37C, 5% CO2,
overnight. Then medium was refreshed and cells were analyzed
after 72 h of treatment. Stable cell line was selected with 5 g/mL
blasticidin.
Cell death induction and quantiﬁcation
Tumor cells were treated with OXP (lot# R01730), cisplatin
(cis-diamminedichloroplatinum(II), CDDP, lot# PR00202)
(both Accord) or mitoxantrone (MTX, Sandoz, lot# D50333A)
to induce cell death. Cell death was assessed by double staining
with annexin V ﬂuorescein isothiocyanate-FITC (AnnV-FITC,
BD Bioscience, catalog# C34554) and DAPI (Sigma-Aldrich,
catalog# 32670). Brieﬂy, cells were collected, washed with PBS
and incubated with AnnV-FITC (1:40), CaCl2 (1M, 1:666) in
PBS on ice, in the dark for 15 min. An equal volume of DAPI
in PBS (ﬁnal concentration 1:2000) was added immediately
prior measurement by ﬂow cytometry.
Flow cytometric analysis of ecto-CRT and ecto-HSP70
6£ 104 tumor cells were let adhere in 24-well plates and treated
with OXP or CDDP for 24 or 48 h. Subsequently, cells were
harvested with cold TEN buffer (40 mM Tris, 150 mM NaCl,
10 mM EDTA, pH 7.8), transferred to a 96-well plate and
washed twice with PBA. After incubation with a Fc-receptor
blocking buffer (2% human or murine serum in PBS, 15 min at
4C) cells were stained for 30 min at 4C with a primary anti-
body in PBA, followed by extensive washing and incubation
with an Alexa488-conjugated monoclonal secondary antibody
Figure 7. Human CD1cC DCs mediate T cell activation against chemotherapy treated-tumor cells. The ability of CD16C, CD1cC, and pDCs to induce T cell proliferation
upon co-culture with control (white), OXP (gray), or CDDP (black) treated-tumor cells was determined in a mixed lymphocyte reaction. FACS sorted DCs were co-cultured
with allogeneic CFSE-labeled peripheral blood lymphocytes (PBLs) for 5 d. (A) PBL proliferation was measured as the percentage of CD3C cells showing CFSE dilution and
expressed relative to CD3C cells cultured in medium. (B) Percentage of proliferated CD3C cells. Data are mean§SEM of at least triplicates of n D 3 (BLM) or one represen-
tative (833KE and 2102EP) experiments. Signiﬁcance was determined by Two-way ANOVA, p< 0.01.
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(Goat-anti-Mouse IgG1, Life Technologies, catalo#A-21121) in
PBA for 20 min at 4C. Isotype-matched IgG antibodies were
used as control. Surface expression of CRT (anti-CRT, clone
ab2907, Abcam, catalog# ab2907; anti-CRT-PE, clone FMC 75,
Enzo Life Sciences, catalog# ADI-SPA-601PE-F) and Hsp70
(anti-HSP70, clone C92F3A-5, Enzo Life Sciences, catalog#
ADI-SPA-810-D) was analyzed by ﬂow cytometry (Table S1).
Detection of ATP and HMGB1 release
Tumor cells (6 £ 104) were adhered in 24-well plates in 1ml of
heat-inactivated complete medium and treated with OXP or
CDDP for 24 or 48 h. Supernatants were collected, dying ﬂoating
cells removed by centrifugation and supernatants frozen immedi-
ately. ATP secretion was measured with the ENLITEN ATP Assay
(Promega, catalog# FF2000) according to the manufacturer’s pro-
tocol. HMGB1 release was assessed by enzyme-linked immunosor-
bent assay (ELISA, IBL International, catalog# ADI-SPA-810-D)
according tomanufacturer’s instructions.
Isolation of human blood immune cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats obtained from healthy volunteers (Sanquin),
after written informed consent and according to institutional
guidelines, and puriﬁed via centrifugation over a ﬁcoll density
gradient (Axis-Shield) in SepMate tubes (Stemcell technolo-
gies). Isolation of human blood DC subsets was achieved by a
sequence of negative and positive selection steps using mag-
netic beads (Human CD16C Monocyte Isolation Kit, catalog#
130-091-765; Human CD1cC (BDCA-1) Dendritic Cell Isola-
tion Kit, catalog# 130-090-506; Human CD304C (BDCA-4/
Neuropilin-1) MicroBead Kit, catalog# 130-090-512; all Milte-
nyi Biotec). DC purity was assessed by staining with primary
labeled antibodies (see also Table S1): anti-CD1c-PE (Miltenyi
biotec, clone AD5-8E7, catalog# 130-090-508), anti-CD11c-
APC (Miltenyi biotec, clone MJ4-27G12, catalog# 130-092-
412), anti-CD20-APC (eBioscience, clone 2H7, catalog#
17-0209), anti-CD15-FITC (Miltenyi biotec, clone VIMC6, cat-
alog# 130-081-101), anti-CD56-PE (IQ Products, clone MOC-
1, catalog# IQP-114R), anti-CD123-APC (Miltenyi biotec,
clone AC145, catalog# 130-090-901) and anti-CD303-PE (Mil-
tenyi biotec, clone AC144, catalog# 130-090-511). Purity levels
higher than 98% were achieved, determined by ﬂow cytometry.
Peripheral blood leukocytes (PBLs) were isolated from PBMCs
by depletion of monocytes via adherence to plastic culture
ﬂasks (1 h at 37C). Floating cells (PBLs) were collected and
re-suspended in X-VIVO-15 medium (Lonza, catalog#
BE04-418Q) supplemented with 2% human serum (HS,
Sanquin).
Microarray data
For the analysis publically available affymetrix, CEL ﬁles contain-
ing expression data of resting human pDCs, CD1cC, and CD16C
were downloaded from ArrayExpress (accession: E-TABM-34).
Data have been published by others.51 Raw ﬁles were processed
in the R programming environment and intensity values across
the different datasets were normalized using the RMA
normalization function of the affy package.52 Speciﬁc annotation
packages for human were used to map array probe identiﬁers to
corresponding species-speciﬁc gene symbols. In case of redun-
dant probes, the probes with highest summed intensity of all
samples were considered. The normalized log2 transformed data
sets was z-scored (setting the data to a mean D 0 and a variance
D 1) and heat maps were generated using freely availably GeneE
program (http://www.broadinstitute.org/).
Immunoﬂuorescence
For evaluation of CRT expression, BLM cells were cultured on
glass coverslips and treated overnight with 50 mM OXP,
66 mMCDDP, 1 mMMTX or left untreated. Cells were washed,
ﬁxed in 0.25% paraformaldehyde (PFA) in PBS for 5 min at RT.
Cells were blocked and subsequently incubated with wheat
germ agglutinin-biotinylated (WGA) for 45 min at 4C. After
extensive wash, cells were stained with primary anti-CRT anti-
body (Abcam, clone ab2907, Table S1) in cold confocal laser
scanning microscope (CLSM) buffer (3% bovine serum albu-
min, 50 mM Glycine in PBS) for 30 min at RT, followed by
incubation with secondary Alexa conjugates in cold CLSM
blocking buffer, for 20 min at RT. Cells were then ﬁxed in 4%
PFA/PBS for 20 min at RT. Nuclei were stained with DAPI
(1:3000) in CLSM for 5 min at RT. Samples were imaged with
an Olympus FV1000 Confocal Laser Scanning Microscope.
Images were analyzed using the open source-imaging platform,
Fiji (imageJ 64 Bit for Windows).
Co-cultures and uptake assays
Tumor cells were stained with 2 mM of the ﬂuorescent probe 5
(6)-Carboxyﬂuorescein diacetate N-succinimidyl ester (CFSE,
Invitrogen, Thermo Fisher Scientiﬁc, catalog# C34554), accord-
ing to manufacturer’s instructions. Fluorescently–labeled
(CFSE or GFP) tumor cells were seeded in T75 ﬂasks (Corn-
ing), adhered and treated with OXP or CDDP. After treatment,
tumor cells (5 £ 105 cells, target) and DCs (5 £ 105 cells, effec-
tor) were co-cultured at a 1:1 ratio in Falcon tubes (BD Falcon)
in X-VIVO-15 supplemented with 2% HS (ﬁnal concentration
1 £ 106/mL). Co-cultures were stained with an APC-labeled
primary antibody recognizing a speciﬁc DC surface marker
(CD11c for CD1cC and CD16C DCs, CD123 for pDCs; see also
Table S1) and analyzed by ﬂow cytometry. Extent of phagocy-
tosis was determined as the percentage of double positive
events (i.e., CD11cC or CD123C-APC/GFPC or CFSEC). For
blocking experiments, tumor cells were pre-incubated (30 min
at 4C) with blocking agents or negative controls: CRT block-
ing peptide (20 mg/mL, MBL International, catalog# JM-
3077BP-50), irrelevant gp100 peptide272-300 (20 mg/mL, JPT),
anti-CD91 (20 mg/mL, Thermo Fisher Scientiﬁc, clone 8G1,
catalog# MA1-27198), or IgG1, k (20 mg/mL, Biolegend, clone
MG1-45). Extra volume blocking agents or matched controls
were added to co-cultures at same ﬁnal concentration.
Flow cytometric analysis of DC maturation
Phenotypical assessment of DC maturation after 48 h of co-cul-
ture with tumor cells was performed by ﬂow cytometry. Brieﬂy,
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cells were washed in PBA, incubated with Fc-receptor blocking
buffer (2% HS in PBS, 15 min at 4C) and subsequently stained
with primary antibodies in PBA (30 min at 4C). Monoclonal
directly labeled anti-human antibodies used were (Table S1):
anti-CD11c-APC (Miltenyi biotec, clone MJ4-27G12, catalog#
130-092-412), anti-CD123-APC (Miltenyi biotec, clone AC145,
catalog# 130-090-901), anti-CD80-PECy7 (BD PharMingen,
clone L307.4, catalog# 561135), anti-CD86-PECy7 (BD Phar-
Mingen, clone 2331, catalog# 561128), anti-HLA-ABC-PE (BD
PharMingen, clone G46-2.6, catalog# 555553), and anti-HLA-
DR-PE (BD PharMingen, clone G46-6, catalog# 555812).
Appropriate isotype controls were included. Geometric mean
ﬂuorescence intensity (GeoMFI) of maturation markers was
assessed on CD11cC (for CD1cC and CD16C DCs) or CD123C
(for pDCs) populations. As a positive control, DCs were stimu-
lated with poly I:C (CD1cC and CD16C DCs, 2 mg/mL, Enzo
Life Science, catalog# ALX-746-021-M005) or R848 (pDCs,
4 mg/mL, Enzo Life Science, catalog# ALX-420-038-M025). To
improve in vitro pDC viability, IL-3 (10 ng/mL, Cellgenix, cata-
log# 1002-050) was added to culture medium.
Cytokine quantiﬁcation
Supernatants from tumor cell-DC co-cultures (18 h) were col-
lected, dying ﬂoating cells removed by centrifugation and
supernatants frozen immediately for detection of secreted cyto-
kines. Human Th1/Th2 cytokines (IFNg, IL-2, IL-4, IL-5, IL-
10, IL-12 (p70), TNF-a, and TNF-b) were quantiﬁed with a
multiplex FlowCytomix kit (eBioscience, BMS810FF) according
to the manufacturer’s instructions.
DC sorting and mixed lymphocyte reaction (MLR)
Tumor-DC co-cultures were established as described above. After
wash in cold wash buffer (PBS/0.1% BSA/5 mM EDTA) and incu-
bation in Fc-receptor blocking buffer (2% HS in wash buffer,
15 min at 4C), cells were stained with sterile primary antibodies in
wash buffer (20 min at 4C). The following antibodies were used
(Table S1): anti-HLA-DR-PECy7 for all subsets (BD Biosciences,
clone L243, catalog# 335813), anti-CD1c-PE for CD1cC DCs (Mil-
tenyi biotec, clone AD5-8E7, catalog# 130-090-508), anti-CD16-
APC for CD16C DCs (Miltenyi biotec, clone VEP13, catalog# 130-
098-101), and anti-CD304-PE for pDCs (Miltenyi biotec, clone
AD5-17F6, catalog# 130-090-533). Sorting of DCs was performed
using a Fluorescence Activated Cell Sorter Aria (FACSAria, BD
Bioscience), based on FSC/SSC properties and positivity for DC
markers (Fig. S5). Allogeneic PBLs were stained with 5 mM CFSE
(Invitrogen), according to manufacturer’s instructions and added
to the sorted DCs at a ratio of 5:1 (Lymphocytes:DCs), for an addi-
tional period of 5 d, in 2% HS X-VIVO-15. After 5 d, co-cultures
were stained with a primary anti-CD3-BV421 antibody (BD Hori-
zon, clone SK7, catalog# 563798) and analyzed by ﬂow cytometry.
The percentage of proliferating T cells (CD3C) was determined by
assessing CFSE dilution in the fraction of CD3C cells.
Statistical analysis
Unless otherwise indicated, experiments were performed at
least three times, yielding comparable results. Data were
analyzed by means of Prism v. 5.03 (GraphPad Software). Sta-
tistical signiﬁcance was assessed by One-way Anova, followed
by a Dunnett’s post-test or Two-way Anova, followed by a Bon-
ferroni’s post-test, as appropriate. p values <0.05 were consid-
ered as statistically signiﬁcant.
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